← Leaderboards
Jun Luo
Johns Hopkins University
$3,173,526
Attributed
$3,914,676
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $513K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,914,676 · 4
By mechanism
R01$3,321,480 · 2
P50$318,936 · 1
R21$274,260 · 1
Top collaborators
- Emmanuel S. Antonarakis4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Paul F Worley$57,319,879
- Peter P Zandi$14,805,431
- Andrea L Cox$41,369,991
- Samuel R Denmeade$5,431,317
- Kenneth J. Pienta$43,861,680
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateGenomicsBloodMutationProspectiveResistanceAbirateroneClinical ManagementPharmaceutical PreparationsResponseTumorTranscriptome SequencingAndrogen ReceptorTissuesSpecimenBlood SpecimenMolecularStandard Of CareCastration Resistant Prostate CancerLiquid BiopsyBaseFda ApprovedEvaluationClinical Trials
Grant awards (13)
Developmental Research Program$161,736
P50 · FY2025 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$355,850
R01 · FY2024 · CA · contact PI
Developmental Research Program$157,200
P50 · FY2024 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$367,087
R01 · FY2023 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$367,087
R01 · FY2022 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$374,578
R01 · FY2021 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$374,578
R01 · FY2020 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2018 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2017 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2016 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2015 · CA · contact PI
Premalignant Prostate Markers That Forebode Malignancy$135,710
R21 · FY2006 · CA · contact PI
Premalignant Prostate Markers That Forebode Malignancy$138,550
R21 · FY2005 · CA